IONS vs. ALKS, IMGN, FOLD, MDGL, UTHR, DVAX, ALNY, ELAN, RETA, and KRTX
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Alkermes (ALKS), ImmunoGen (IMGN), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), United Therapeutics (UTHR), Dynavax Technologies (DVAX), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Reata Pharmaceuticals (RETA), and Karuna Therapeutics (KRTX). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Alkermes has a net margin of 7.04% compared to Ionis Pharmaceuticals' net margin of -48.81%. Alkermes' return on equity of 2.33% beat Ionis Pharmaceuticals' return on equity.
Alkermes received 6 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 70.70% of users gave Alkermes an outperform vote while only 60.38% of users gave Ionis Pharmaceuticals an outperform vote.
Alkermes has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals currently has a consensus target price of $48.10, suggesting a potential upside of 2.98%. Alkermes has a consensus target price of $33.33, suggesting a potential upside of 17.41%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than Ionis Pharmaceuticals.
In the previous week, Ionis Pharmaceuticals had 20 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Ionis Pharmaceuticals and 2 mentions for Alkermes. Alkermes' average media sentiment score of 0.94 beat Ionis Pharmaceuticals' score of 0.71 indicating that Alkermes is being referred to more favorably in the news media.
Ionis Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Alkermes beats Ionis Pharmaceuticals on 15 of the 18 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ionis Pharmaceuticals Competitors List
Related Companies and Tools